Clinical trials: Type 2 Diabetes Patients
Type 2 Diabetes Mellitus, Hypercholesterolemia
Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.
This is a 16-week double-blind, placebo-controlled (for colesevelam hydrochloride (HCl)) study in the type 2 diabetic subjects and pre-diabetic subjects.
- Conditions
- Type 2 Diabetes Mellitus, Hypercholesterolemia, Pre-diabetes
- Trial name
- NCT00570739
- Testing
- Metformin HCl tablets and Colesevelam tablets, Colesevelam
- Where
- 31 sites in United States, Colombia and 2 more
- Volunteers
- 502 people
- Sponsor
- Daiichi Sankyo
Type 2 Diabetes Mellitus
Initial Combination With Pioglitazone Study (0431-064)
A clinical study to evaluate the safety and efficacy of the initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes mellitus not on treatment with insulin or oral antihyperglycemic therapy.
- Trial name
- NCT00397631
- Testing
- sitagliptin 100 mg q.d./pioglitazone 30 mg q.d
- Volunteers
- 520 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Efficacy and Safety Study of MP-513 in Combination With Thiazolidinedione in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of MP-513 (Teneligliptin) in combination with thiazolidinedione (pioglitazone) in patients with type 2 Diabetes for 12 weeks administration and to evaluate the…
- Trial name
- NCT01026194
- Testing
- Teneli / Teneli + pio
- Where
- Japan
- Volunteers
- 204 people
- Sponsor
- Tanabe Pharma Corporation
Type 2 Diabetes Mellitus
Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3)
The purpose of this study is to compare the effects of 2.0 mg exenatide once weekly and insulin glargine, titrated to glucose targets using the algorithm described by Yki- Järvinen et al.(2007), with respect to glycemic…
- Trial name
- NCT00641056
- Testing
- Exenatide Once Weekly, Insulin Glargine
- Where
- 75 sites in United States, Australia and 14 more
- Volunteers
- 467 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea
Primary Objective: To demonstrate the superiority of once weekly injection of efpeglenatide in comparison to placebo in glycated hemoglobin (HbA1c) change in participants with type 2 diabetes mellitus (T2DM) inadequately…
- Trial name
- AMPLITUDE-S (NCT03770728)
- Testing
- Efpeglenatide SAR439977, Background therapy: Metformin alone or in combination with SU
- Where
- 48 sites in United States, China and 1 more
- Volunteers
- 312 people
- Sponsor
- Sanofi
Acromegaly, Type 2 Diabetes Mellitus
Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)
Growth hormone (GH) and Insulin-like growth factor-I (IGF-I) secretion are altered in acromegaly and type 2 Diabetes Mellitis (DM).
- Trial name
- NCT00915954
- Testing
- Oral Glucose Tolerance Test, Subcutaneous administration of recombinant human IGF-1
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Type II Diabetes
Measuring the Preferences of Patients With Type II Diabetes Using Best-worst Scaling and Discrete Choice Experiment
In 2012, the FDA Center for Devices and Radiological Health (CDRH) issued guidance to clarify the principal benefit-risk factors FDA considers during the reviews for premarket approval applications and de novo classification…
- Trial name
- NCT02637622
- Testing
- Best-Worst Scaling (Case 2), Discrete Choice Experiment
- Where
- United States
- Volunteers
- 1,103 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Type 2 Diabetes
Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s)
This long term, placebo-controlled trial is intended to assess the efficacy and safety of exenatide, dosed twice a day, in Japanese patients with Type 2 Diabetes who are treated with oral antidiabetic(s) but not well controlled.
- Trial name
- NCT00577824
- Testing
- exenatide
- Where
- 12 sites in Japan
- Volunteers
- 181 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus
Study to investigate the safety and efficacy of long-term daily use of Trazenta® Tablets as monotherapy in patients with type 2 diabetes mellitus and to assess baseline characteristics of patients with type 2 diabetes mellitus…
- Trial name
- NCT01650259
- Testing
- OAD, Trazenta
- Where
- Japan
- Volunteers
- 4,876 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
Study D5553C00002 is a multicenter, randomized, double-blind, placebo-controlled, parallel group, Phase 3 study to compare the safety and efficacy of exenatide once weekly (EQW) added to titrated basal insulin glargine with or…
- Trial name
- NCT02229383
- Testing
- Exenatide
- Where
- 123 sites in United States, Hungary and 4 more
- Volunteers
- 464 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
My Diabetes Care: A Scalability and Usability Study
The purpose of this study is to conduct a prospective, longitudinal study on the My Diabetes Care (MDC) mobile intervention to assess usage patterns, user experience, and to uncover errors in functionality prior to a larger…
- Trial name
- NCT05448105
- Testing
- My Diabetes Care (MDC)
- Where
- 2 sites in United States
- Volunteers
- 67 people
- Sponsor
- Vanderbilt University Medical Center
Type 2 Diabetes Mellitus
Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin
This study will assess safety and efficacy of exenatide in combination with a thiazolidinedione (TZD) and a TZD plus metformin over 26 weeks in adult patients with type 2 diabetes who have not achieved adequate glycemic control.
- Trial name
- NCT00603239
- Testing
- exenatide
- Where
- 25 sites in United States, Canada and 3 more
- Volunteers
- 165 people
- Sponsor
- AstraZeneca
Ischemic Heart Disease, Ischemic Stroke
Study to Compare 2 Doses of Polycap Versus Single Dose of Polycap With or Without Pottasium
This is a randomized double blind 2x2 factorial controlled trial to evaluate efficacy tolerability of low strength Polycap versus two doses of low strength Polycap in patients with stable cardiovascular disease in reducing blood…
- Conditions
- Ischemic Heart Disease, Ischemic Stroke, Peripheral Vascular Disease, Type 2 Diabetes Mellitus
- Trial name
- TIPSK (NCT01404078)
- Testing
- Single Dose Polycap, Double dose Polycap
- Volunteers
- 518 people
- Sponsor
- St. John's Research Institute
Diabetes Mellitus, Type 2
A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes
A study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes.
- Trial name
- NCT00838916
- Testing
- albiglutide, insulin glargine
- Where
- 337 sites in United States, Russia and 2 more
- Volunteers
- 779 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes Mellitus
Efficacy and Safety Study of MP-513 in Combination With Sulfonylurea in Patients With Type 2 Diabetes
The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) in combination with Sulfonylurea in patients with type 2 Diabetes for 12 weeks administration and to evaluate the safety and efficacy of…
- Trial name
- NCT00974090
- Testing
- Teneli / Teneli + SU
- Where
- Japan
- Volunteers
- 194 people
- Sponsor
- Tanabe Pharma Corporation
Type 2 Diabetes Mellitus (T2DM)
Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin
To compare a therapeutic strategy combining vildagliptin+metformin + Basal Insulin versus SU+metformin + Basal Insulin on the incidence of hypoglycemic events over 24 weeks.
- Trial name
- ADDONIS (NCT01871558)
- Testing
- Vildagliptin, Metformin, sulfonylurea (SU)
- Where
- 19 sites in France
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
Feasibility Trial Using an Inpatient Insulin Dosing Calculator
The goal of this feasibility trial is to test whether a novel insulin dosing calculator can improve blood glucose management for patients with type 2 diabetes mellitus on hospital admission.
- Trial name
- NCT06206525
- Testing
- Initial insulin dosing calculator
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- University of Washington
Diabetes, Type 2
Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus
B2611002 is designed to study how safe and effective an investigational medication (PF-04991532) is in people with Type 2 diabetes. Subjects in the study will receive 1 of 5 treatments for 3 months.
- Trial name
- NCT01336738
- Testing
- 150 mg PF-04991532, 450 mg PF-04991532, 750 mg PF-04991532
- Where
- 44 sites in United States, Canada and 5 more
- Volunteers
- 266 people
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy
The purpose of this study was to evaluate the efficacy and safety of 24-week treatment with metformin hydrochloride 500 mg once daily added on to alogliptin (SYR-322) 25 mg in type 2 diabetic patients with inadequate glycemic…
- Trial name
- NCT02068443
- Testing
- Alogliptin, Metformin hydrochloride
- Where
- 27 sites in Japan
- Volunteers
- 374 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)
A study to evaluate the efficacy and safety of MK0431A in comparison to a commonly used medication in patients with type 2 diabetes
- Trial name
- NCT00532935
- Testing
- sitagliptin phosphate (+) metformin hydrochloride, Comparator: pioglitazone
- Volunteers
- 517 people
- Sponsor
- Merck Sharp & Dohme LLC